California Polytechnic State University
San Luis Obispo, California, 93405, United States
NCT Number: NCT03771066
This study examine oral bisphenol A consumption on muscle insulin sensitivity and hepatic glucose suppression. Half of the participants will receive a diet plus BPA and the other half will receive a diet plus no bisphenol A.
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Not applicable
San Luis Obispo, California, 93405, United States
Evidence linking bisphenol A exposure with diabetes risk remains mainly associative in nature, and mechanism linking bisphenol A to type 2 diabetes remains unclear. The investigator's preliminary data suggests that in young adults, single oral BPA consumption significantly decreased glucose, insulin, and C-Peptide responses to an oral glucose tolerance test, suggesting that immediate consumption of bisphenol A has an effect on muscle insulin sensitivity, hepatic glucose suppression and/or digestion and absorption to lower blood glucose, insulin, and C-Peptide concentrations. The present experimental study evaluating the effects of bisphenol A over several days on the pathogenesis of type 2 diabetes will directly assess each of these potential mechanisms using gold standard measures (euglycemic hyperinsulinemic clamp technique and hepatic glucose suppression with glucose stable isotope infusion, and fecal microbiota).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Vanilla wafer cookie with bisphenol A administered
Vanilla wafer cookie with no bisphenol A
Time frame: Baseline and 4 days
Three hour euglycemic hyperinsulinemic clamp technique with stable glucose isotope infusion to determine rate of glucose disposal
Time frame: Baseline and 4 days
Ninety minutes stable glucose isotope infusion to determine rate of hepatic glucose appearance
Time frame: Baseline and 4 days
Fasting blood sample for insulin concentration
Time frame: Baseline and 4 days
Fasting blood sample for glucose concentration
Time frame: Baseline and 4 days
Fasting blood sample for c-peptide concentration
Time frame: Baseline and 4 days
Fasting blood sample for proinsulin
Time frame: Baseline and 4 days
Fasting blood sample for adiponectin
Time frame: Baseline and 4 days
Fasting blood sample for 17-beta estradiol
Time frame: Baseline and 4 days
Fecal microbiome concentration of firmicutes
Time frame: Baseline and 4 days
Fecal microbiome concentration of clostridia
California Polytechnic State University-San Luis Obispo
Other
Randomized Trial Examining Oral Consumption of Bisphenol A on Type 2 Diabetes Risk Markers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04529473
Glucose Intolerance, Glucose Metabolism Disorders
Chicago, Illinois, United States
View Trial DetailsNCT05558488
Acid-Base Imbalance, Acidosis
Poznan, Greater Poland Voivodeship, Poland
View Trial DetailsNCT06878781
Behavior, Fasting
Mexico City, Mexico
View Trial DetailsNCT06802341
Body Weight, Glucose Metabolism Disorders
Singapore
View Trial Details